Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load.


Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
05 2019
Historique:
received: 16 04 2018
revised: 31 10 2018
accepted: 31 10 2018
pubmed: 10 1 2019
medline: 27 4 2019
entrez: 10 1 2019
Statut: ppublish

Résumé

A hallmark of chronic HBV (cHBV) infection is the presence of impaired HBV-specific CD8+ T cell responses. Functional T cell exhaustion induced by persistent antigen stimulation is considered a major mechanism underlying this impairment. However, due to their low frequencies in chronic infection, it is currently unknown whether HBV-specific CD8+ T cells targeting different epitopes are similarly impaired and share molecular profiles indicative of T cell exhaustion. By applying peptide-loaded MHC I tetramer-based enrichment, we could detect HBV-specific CD8+ T cells targeting epitopes in the HBV core and the polymerase proteins in the majority of 85 tested cHBV patients with low viral loads. Lower detection rates were obtained for envelope-specific CD8+ T cells. Subsequently, we performed phenotypic and functional in-depth analyses. HBV-specific CD8+ T cells are not terminally exhausted but rather exhibit a memory-like phenotype in patients with low viral load possibly reflecting weak ongoing cognate antigen recognition. Moreover, HBV-specific CD8+ T cells targeting core versus polymerase epitopes significantly differed in frequency, phenotype and function. In particular, in comparison with core-specific CD8+ T cells, a higher frequency of polymerase-specific CD8+ T cells expressed CD38, KLRG1 and Eomes accompanied by low T-bet expression and downregulated CD127 indicative of a more severe T cell exhaustion. In addition, polymerase-specific CD8+ T cells exhibited a reduced expansion capacity that was linked to a dysbalanced TCF1/BCL2 expression. Overall, the molecular mechanisms underlying impaired T cell responses differ with respect to the targeted HBV antigens. These results have potential implications for immunotherapeutic approaches in HBV cure.

Identifiants

pubmed: 30622109
pii: gutjnl-2018-316641
doi: 10.1136/gutjnl-2018-316641
doi:

Substances chimiques

Gene Products, pol 0
P protein, Hepatitis B virus 0
Viral Core Proteins 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

905-915

Commentaires et corrections

Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Anita Schuch (A)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Faculty of Biology, University of Freiburg, Freiburg, Germany.

Elahe Salimi Alizei (E)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Faculty of Chemistry and Pharmacy, University of Freiburg, Freiburg, Germany.

Kathrin Heim (K)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Faculty of Biology, University of Freiburg, Freiburg, Germany.

Dominik Wieland (D)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Michael Muthamia Kiraithe (MM)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Janine Kemming (J)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Faculty of Biology, University of Freiburg, Freiburg, Germany.

Sian Llewellyn-Lacey (S)

Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Özlem Sogukpinar (Ö)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Yi Ni (Y)

Department of Infectious Diseases, Molecular Virology, Heidelberg University Hospital, Heidelberg, Germany.

Stephan Urban (S)

Department of Infectious Diseases, Molecular Virology, Heidelberg University Hospital, Heidelberg, Germany.
German Center for Infection Research (DZIF), Partner Site Heidelberg, Heidelberg, Germany.

Peter Zimmermann (P)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Faculty of Biology, University of Freiburg, Freiburg, Germany.

Michael Nassal (M)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Florian Emmerich (F)

Institute for Cell and Gene Therapy, University Hospital Freiburg, Freiburg, Germany.

David A Price (DA)

Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Bertram Bengsch (B)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Hendrik Luxenburger (H)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Christoph Neumann-Haefelin (C)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Maike Hofmann (M)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Robert Thimme (R)

Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH